SGLT2 Inhibitor–Induced Euglycemic Diabetic Ketoacidosis: A Case Report
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Euglycemic diabetic ketoacidosis is a rare but serious adverse effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors. We present a case of a woman in her 40s with type 2 diabetes mellitus hospitalized for revascularization for moyamoya disease who developed empagliflozin-associated euglycemic diabetic ketoacidosis despite having stopped the medication before admission. Surgical stress, acute postoperative illness, and decreased carbohydrate intake are postulated to be contributing factors to the development of ketosis in this patient, while near-normal glucose levels initially suggested nondiabetic ketoacidosis physiology and led to delayed diagnosis and treatment. Patients with type 2 diabetes mellitus may develop diabetic ketoacidosis during states of relative insulinopenia, most frequently from inadequate medication or intercurrent illness. During periods of carbohydrate deficiency, volume depletion, and upregulation of counter-regulatory stress hormones, SGLT2 inhibitor therapy can promote lipolysis and ketogenesis while maintaining euglycemia. Clinical considerations to ensure safe SGLT2 inhibitor therapy include appropriate holding parameters, timely diagnosis of euglycemic diabetic ketoacidosis, and recognition that the pharmacologic effects of SGLT2 inhibitor treatment may persist beyond several half-lives of elimination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
Handelsman, Y., Henry, R. R., Bloomgarden, Z. T., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Ferrannini, E., Fonseca, V. A., Garber, A. J., Grunberger, G., et al. (2016) · Endocrine Practice · doi:10.4158/ep161292.ps · Cited by 358 · cited 1×
“Endocrinology clinical practice guidelines recommend stopping treatment with SGLT2 inhibitors at least 24 hours before elective surgery, invasive procedures, and anticipated severe stressful physical activity and/or metabolically challenging activities, such as marathon running.(18) However, case reports suggest that…”
BackgroundRisk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor
Fralick, M., Schneeweiss, S., & Patorno, E. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1701990 · Cited by 334
Euglycemic diabetic ketoacidosis
Barski, L., Eshkoli, T., Brandstaetter, E., & Jotkowitz, A. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.03.014 · Cited by 176
Cited by
Seki, H., Ideno, S., Shiga, T., Watanabe, H., Ono, M., Motoyasu, A., Noguchi, H., Kondo, K., Yoshikawa, T., Hoshijima, H., et al. (2023) · Journal of Anesthesia · doi:10.1007/s00540-023-03174-8 · Cited by 56
Bamgboye, A. O., Oni, I. O., & Collier, A. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03051-3 · Cited by 48
Postoperative outcomes among sodium-glucose cotransporter 2 inhibitor users
Tallarico, R. T., Jing, B., Lu, K., Chawla, S. A., Luo, Y., Badathala, A., Chen, C. L., Wallace, A. W., & Legrand, M. (2025) · JAMA Surgery · doi:10.1001/jamasurg.2025.0940 · Cited by 40
Metadata
- Authors
- Wang, K. M., & Isom, R. T.
- Venue
- Kidney Medicine
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 2
- Issue
- 2
- Pages
- 218-221
- ISSN
- 2590-0595 (ISSN-L)
- OpenAlex
- W3008062346
- Cited by
- 67
- References
- 6
- FWCI
- 5.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SGLT2 Inhibitor–Induced Euglycemic Diabetic Ketoacidosis: A Case Report. https://app.cochat.ai/papers/10.1016/j.xkme.2019.12.006
- The paper
- Wang, K. M., & Isom, R. T. (2020). SGLT2 Inhibitor–Induced Euglycemic Diabetic Ketoacidosis: A Case Report. Kidney Medicine. https://doi.org/10.1016/j.xkme.2019.12.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.